Clinicopathological features of MRONJ in this study
| Variable | Drug suspension (n=18) | Non-drug suspension (n=6) |
|---|---|---|
| Sex | ||
| Male | 1 | 1 |
| Female | 17 | 5 |
| Age (yr) | 76.17±5.17 (68-85) | 77.33±3.64 (73-82) |
| BP type by subclass | ||
| Alendronate | 8 (44.4) | 3 (50.0) |
| Risedronate | 4 (22.2) | 1 (16.7) |
| Ibandronate | 9 (50.0) | 2 (33.3) |
| Pamidronate | - | - |
| Zoledronate | 1 (5.6) | - |
| Route of administration | ||
| Oral | 10 (55.6) | 6 (100) |
| IV | 6 (33.3) | - |
| Oral+IV | 2 (11.1) | - |
| Duration of BP use (yr) | 4.40±2.70 (0.5-10) | 8.00±6.30 (3-20) |
| Duration of BP suspension (mo) | 5.64±3.37 (3-12) | - |
| Preoperative stage | ||
| 0 | 1 (5.6) | - |
| 1 | - | - |
| 2 | 10 (55.6) | 2 (33.3) |
| 3 | 7 (38.9) | 4 (66.7) |
| Outcome assessment | ||
| Absent | 13 (72.2) | - |
| Reduced | 2 (11.1) | 2 (33.3) |
| Unchanged | 3 (16.7) | 2 (33.3) |
| Increased | - | 2 (33.3) |
| Trigger | ||
| Spontaneous | 2 (11.1) | - |
| Odontogenic infection | 5 (27.8) | - |
| Tooth extraction | 9 (50.0) | 1 (16.7) |
| Implant procedure | 2 (11.1) | - |
| Implant removal | - | 3 (50.0) |
| Peri-implantitis | - | 1 (16.7) |
| Ill-fitting denture | - | 1 (16.7) |
| Other systemic diseases | ||
| None | 2 (11.1) | 2 (33.3) |
| Hypertension | 10 (55.6) | 3 (50.0) |
| Diabetes mellitus | 5 (27.8) | 3 (50.0) |
| Cardiovascular | 1 (5.6) | - |
| Hyperlipidemia | 1 (5.6) | 1 (16.7) |
| Rheumatoid arthritis | 1 (5.6) | - |
| Pulmonary disease | 1 (5.6) | - |
| Smoking | - | - |
(MRONJ: medication-related osteonecrosis of the jaw, BP: bisphosphonate, IV: intervention)
Values are presented as number only, mean±standard deviation (range), or number (%).